Breast SPORE Research

Seattle Cancer Consortium Breast SPORE

Breast SPORE Research

graphic representing key components of Breast Cancer SPORE

The SPORE research projects afford both short- and long-term translational rewards and potential for new discoveries that will impact important aspects of breast cancer care. The SPORE includes four supporting cores: Leadership, Specimen Acquisition and Pathology, Clinical, and Biostatistics and is enhanced by a Developmental Research Program, and a Career Enhancement Program.

These elements, along with the existing highly interactive and interdisciplinary environment and outstanding institutional support for breast cancer research in the Fred Hutch / UW Cancer Consortium, ensure a successful translational SPORE program in breast cancer.


  • The Leadership Core provides the overall context for the translational activities of the SPORE and builds on established interdisciplinary collaborations.
  • Our Specimen Acquisition and Pathology Core coordinates with the promotion of new research greatly aids translation of basic discoveries into experiments involving human samples.
  • The Clinical Core takes advantage of Fred Hutch/UW Consortium research, clinical strengths and institutional alliances to maximize exchange of ideas and facilitate translation, both to and from the clinic.
  • The Biostatistics Core links study design, data collection, measurements, and analysis to the critical hypotheses and questions studied by SPORE investigators whose research involves basic sciences, epidemiology, population studies, and clinical research.


Our Career Enhancement Program goals are to support junior-level researchers as they become independent and develop into translational breast cancer researchers. The program aims to maintain gender and minority diversity.

Developmental Research Projects fund a broad selection of research on breast cancer etiology, mechanical relapse prevention strategies, metabolic diversity, immunotherapy, radiopharmaceuticals for imaging, gut microbiome, biomarkers of treatment/detection/resistance, and the effect of breast cancer on patient financial status.